High proliferation is associated with inferior outcome in male breast cancer patients

Modern Pathology

Volumn 26, Issue 1, 2013, Pages 87-94

  Nilsson, Cecilia ^a,b   Koliadi, Anthoula ^b   Johansson, Ida ^c   Ahlin, Cecilia ^d   Thorstenson, Sten ^e   Bergkvist, Leif ^a   Hedenfalk, Ingrid ^c   Fjällskog, Marie Louise ^b  

^a Västmanlands County Hospital   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; immunohistochemistry; male

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN D1; KI 67 ANTIGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MITOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR GROWTH;

EID: 84871919562     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.145     Document Type: Article

References (31)

1. Miao H, Verkooijen HM, Chia KS, et al. Incidence andoutcome of male breast cancer: an internationalpopulation-based study. J Clin Oncol 2011;29:4381-4388
2. Czene K, Bergqvist J, Hall P, et al. How to treat malebreast cancer. Breast 2007;16(Suppl 2):S147-S154
3. Nilsson C, Holmqvist M, Bergkvist L, et al. Similaritiesand differences in the characteristics and primarytreatment of breast cancer in men and women-apopulation based study (Sweden). Acta Oncol 2011;50:1083-1088
4. Johansson I, Nilsson C, Berglund P, et al. Geneexpression profiling of primary male breast cancersreveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker.Breast Cancer Res 2012;14:R31
5. Johansson I, Nilsson C, Berglund P, et al. Highresolutiongenomic profiling of male breast cancerreveals differences hidden behind the similarities withfemale breast cancer. Breast Cancer Res Treat 2011;129:747-760
6. Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer.Evolution of treatment and prognostic factors. Analysisof 489 cases. Crit Rev Oncol Hematol 2010;73:246-254
7. Giordano SH, Cohen DS, Buzdar AU, et al. Breastcarcinoma in men: a population-based study. Cancer2004;101:51-57
8. Rayson D, Erlichman C, Suman VJ, et al. Molecularmarkers in male breast carcinoma. Cancer 1998;83:1947-1955
9. Wang-Rodriguez J, Cross K, Gallagher S, et al. Malebreast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of65 cases. Mod Pathol 2002;15:853-861 (Pubitemid 34919778)
10. Colozza M, Azambuja E, Cardoso F, et al. Proliferativemarkers as prognostic and predictive tools in earlybreast cancer: where are we now? Ann Oncol 2005;16:1723-1739 (Pubitemid 41631235)
11. Agarwal R, Gonzalez-Angulo AM, Myhre S, et al.Integrative analysis of cyclin protein levels identifiescyclin b1 as a classifier and predictor of outcomes inbreast cancer. Clin Cancer Res 2009;15:3654-3662
12. Ahlin C, Zhou W, Holmqvist M, et al. Cyclin A is aproliferative marker with good prognostic value innode-negative breast cancer. Cancer Epidemiol BiomarkersPrev 2009;18:2501-2506
13. Luporsi E, Andre F, Spyratos F, et al. Ki-67: level ofevidence and methodological considerations for itsrole in the clinical management of breast cancer:analytical and critical review. Breast Cancer Res Treat2011;132:895-915
14. Michalides R, van Tinteren H, Balkenende A, et al.Cyclin A is a prognostic indicator in early stage breastcancer with and without tamoxifen treatment. Br JCancer 2002;86:402-408 (Pubitemid 34185125)
15. Nimeus-Malmstrom E, Koliadi A, Ahlin C, et al. CyclinB1 is a prognostic proliferation marker with a highreproducibility in a population-based lymph nodenegative breast cancer cohort. Int J Cancer 2010;127:961-967
16. Rudas M, Lehnert M, Huynh A, et al. Cyclin D1expression in breast cancer patients receiving adjuvanttamoxifen-based therapy. Clin Cancer Res 2008;14:1767-1774 (Pubitemid 351469462)
17. Stendahl M, Kronblad A, Ryden L, et al. Cyclin D1overexpression is a negative predictive factor fortamoxifen response in postmenopausal breast cancerpatients. Br J Cancer 2004;90:1942-1948 (Pubitemid 38746334)
18. Kanthan R, Fried I, Rueckl T, et al. Expression of cellcycle proteins in male breast carcinoma. World J SurgOncol 2010;8:10
19. Aaltonen K, Ahlin C, Amini RM, et al. Reliability ofcyclin A assessment on tissue microarrays in breastcancer compared to conventional histological slides.Br J Cancer 2006;94:1697-1702 (Pubitemid 43924935)
20. Ahlin C, Aaltonen K, Amini RM, et al. Ki67 and cyclinA as prognostic factors in early breast cancer. What arethe optimal cut-off values? Histopathology 2007;51:491-498 (Pubitemid 47437828)
21. Miglietta L, Vanella P, Canobbio L, et al. Prognosticvalue of estrogen receptor and Ki-67 index afterneoadjuvant chemotherapy in locally advanced breastcancer expressing high levels of proliferation atdiagnosis. Oncology 2010;79:255-261
22. Pich A, Margaria E, Chiusa L. Proliferative activity is asignificant prognostic factor in male breast carcinoma.Am J Pathol 1994;145:481-489 (Pubitemid 24245848)
23. Bostrom P, Soderstrom M, Palokangas T, et al. Analysisof cyclins A, B1, D1 and E in breast cancer in relationto tumour grade and other prognostic factors. BMC ResNotes 2009;2:140
24. Hwang TS, Han HS, Hong YC, et al. Prognostic value ofcombined analysis of cyclin D1 and estrogen receptorstatus in breast cancer patients. Pathol Int 2003;53:74-80 (Pubitemid 36332370)
25. Lundgren K, Brown M, Pineda S, et al. Effects of cyclinD1 gene amplification and protein expression on timeto recurrence in postmenopausal breast cancer patientstreated with anastrozole or tamoxifen: a TransATACstudy. Breast Cancer Res 2012;14:R57
26. Aaltonen K, Amini RM, Landberg G, et al. Cyclin D1expression is associated with poor prognostic featuresin estrogen receptor positive breast cancer. BreastCancer Res Treat 2009;113:75-82
27. Lehn S, Tobin NP, Berglund P, et al. Down-regulationof the oncogene cyclin D1 increases migratory capacityin breast cancer and is linked to unfavorable prognosticfeatures. Am J Pathol 2010;177:2886-2897
28. Lamb J, Ladha MH, McMahon C, et al. Regulation ofthe functional interaction between cyclin D1 and theestrogen receptor. Mol Cell Biol 2000;20:8667-8675 (Pubitemid 32245900)
29. Neuman E, Ladha MH, Lin N, et al. Cyclin D1 stimulationof estrogen receptor transcriptional activityindependent of cdk4. Mol Cell Biol 1997;17:5338-5347 (Pubitemid 27357632)
30. Callari M, Cappelletti V, De Cecco L, et al. Geneexpression analysis reveals a different transcriptomiclandscape in female and male breast cancer. BreastCancer Res Treat 2010;127:601-610
31. Weber-Chappuis K, Bieri-Burger S, Hurlimann J.Comparison of prognostic markers detected by immunohistochemistryin male and female breast carcinomas.Eur J Cancer 1996;32A:1686-1692 (Pubitemid 26306878)